Modulation of astrocyte reactivity improves functional deficits in mouse models of Alzheimer’s disease

Viral vectors Male JAK2-STAT3 pathway [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology Mice, Transgenic Mouse models Hippocampus Amyloid beta-Protein Precursor Mice 03 medical and health sciences Apolipoproteins E Neuroinflammation Alzheimer Disease Glial Fibrillary Acidic Protein Presenilin-1 Animals Aspartic Acid Endopeptidases RC346-429 Extracellular Signal-Regulated MAP Kinases Maze Learning JAK2-STAT3 pathway 0303 health sciences Amyloid beta-Peptides Research Signaling cascades Excitatory Postsynaptic Potentials Janus Kinase 2 Disease Models, Animal Astrocytes Mutation Reactive astrocytes Neurology. Diseases of the nervous system Amyloid Precursor Protein Secretases Alzheimer’s disease
DOI: 10.1186/s40478-018-0606-1 Publication Date: 2018-10-15T18:39:18Z
ABSTRACT
Astrocyte reactivity and neuroinflammation are hallmarks of CNS pathological conditions such as Alzheimer's disease. However, the specific role of reactive astrocytes is still debated. This controversy may stem from the fact that most strategies used to modulate astrocyte reactivity and explore its contribution to disease outcomes have only limited specificity. Moreover, reactive astrocytes are now emerging as heterogeneous cells and all types of astrocyte reactivity may not be controlled efficiently by such strategies.Here, we used cell type-specific approaches in vivo and identified the JAK2-STAT3 pathway, as necessary and sufficient for the induction and maintenance of astrocyte reactivity. Modulation of this cascade by viral gene transfer in mouse astrocytes efficiently controlled several morphological and molecular features of reactivity. Inhibition of this pathway in mouse models of Alzheimer's disease improved three key pathological hallmarks by reducing amyloid deposition, improving spatial learning and restoring synaptic deficits.In conclusion, the JAK2-STAT3 cascade operates as a master regulator of astrocyte reactivity in vivo. Its inhibition offers new therapeutic opportunities for Alzheimer's disease.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (85)
CITATIONS (168)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....